

1 Full Title: “Effectiveness of whole virus COVID-19 vaccine at protecting health care personnel against  
2 SARS-CoV-2 infections in Lima, Peru”

3  
4 Short Title: “Whole virus vaccine effectiveness among healthcare personnel”

5  
6 Authors:

7 Carmen S Arriola<sup>1</sup>, Giselle Soto<sup>2</sup>, Matthew Westercamp<sup>3</sup>, Susan Bollinger<sup>3</sup>, Angelica Espinoza<sup>2</sup>, Max  
8 Grogl<sup>2</sup>, Alejandro Llanos-Cuentas<sup>4</sup>, Eduardo Matos<sup>5</sup>, Candice Romero<sup>2</sup>, Maria Silva<sup>2</sup>, Rachel Smith<sup>3</sup>,  
9 Natalie Olson<sup>1</sup>, Michael Prouty<sup>2</sup>, Eduardo Azziz-Baumgartner<sup>1</sup>, Fernanda C. Lessa<sup>3</sup>

10 Affiliations:

11 <sup>1</sup>Centers for Disease Control and Prevention, Influenza Division, National Center for Immunization and  
12 Respiratory Diseases (NCIRD), Atlanta, Georgia, USA

13 <sup>2</sup>Naval Medical Research Unit No 6 (NAMRU-6), Lima, Peru

14 <sup>3</sup>Centers for Disease Control and Prevention, Division of Healthcare Quality and Promotion, National  
15 Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Atlanta, Georgia, USA

16 <sup>4</sup>Cayetano Heredia Hospital, Lima, Peru

17 <sup>5</sup>Arzobispo Loayza National Hospital, Lima, Peru

18  
19 Corresponding Author: Carmen Sofia Arriola, Influenza Division, Centers for Disease Control and  
20 Prevention, 1600 Clifton Rd MS A-32, Atlanta, GA 30329, United States; telephone: (404) 718-4589;  
21 fax (404) 639-3866; email: wus3@cdc.gov.

22  
23 Abstract (300w)

24  
25 In February 2021, Peru launched a vaccination campaign among healthcare personnel using BBIBP-  
26 CorV inactivated whole virus (BBIBP-CorV) COVID-19 vaccine. Two doses of BBIBP-CorV vaccine  
27 are recommended, 21 days apart. Data on BBIBP-CorV vaccine effectiveness will inform the use and  
28 acceptance of vaccination with BBIBP-CorV vaccine.

29  
30 We evaluated BBIBP-CorV vaccine effectiveness among an existing multi-year influenza cohort at two  
31 hospitals in Lima. We analyzed data on 290 participants followed between February and May 2021.  
32 Participants completed a baseline questionnaire and provided weekly self-collected anterior nasal swabs  
33 tested for SARS-CoV-2 by rRT-PCR for sixteen weeks. We performed multivariable logistic regression  
34 models adjusting for pre-selected characteristics (age, sex, exposure to COVID-19 patients, work in  
35 intensive care unit or emergency department, BMI, and exposure time in days). BBIBP-CorV vaccine  
36 effectiveness was calculated after the two-week post-vaccination period as  $(1 - \text{Odds Ratio for testing SARS-CoV-2 positive}) \times 100\%$ .

37  
38  
39 SARS-CoV-2 was detected by rRT-PCR among 25 (9%) participants during follow-up (February-May  
40 2021). Follow-up period ranged 1-11 weeks (median: 2 weeks). Among cohort participants who were  
41 fully vaccinated the adjusted vaccine effectiveness against SARS-CoV-2 infection was estimated as 95%  
42 (95% CI: 70%, 99%) and 100% (95% CI: 88%, 100%) for those partially vaccinated.

43  
44 During the study period, vaccination of healthcare personnel with BBIBP-CorV vaccine was effective at  
45 reducing SARS-CoV-2 infections in the weeks immediately following vaccination. This information can  
46 be used to support vaccination efforts in the region, especially among those who could be concerned  
47 about their effectiveness.

48

## 49 Introduction

50

51 Peru is a middle-income country (MIC) disproportionately affected by coronavirus disease (COVID-19)  
52 and struggling to protect its essential workforce [1-4]. Despite early lockdowns, curfews, and other  
53 public health and social measures implemented to reduce disease spread [5], as of May 22, 2021, Peru  
54 had reported 180,764 COVID-19 associated deaths [6], and continues to accrue cases [7]. As in many  
55 other MICs, healthcare services have been overwhelmed with patients, have limited personal protective  
56 equipment, and have delayed and limited COVID-19 vaccination, leading to unrest and strikes among  
57 Peruvian healthcare personnel [8]. COVID-19 vaccination with Sinopharm BBIBP-CorV (Beijing  
58 Institute of Biological Products Coronavirus Vaccine) inactivated whole virus vaccine, hereinafter  
59 referred to as BBIBP-CorV vaccine, was initiated in Peru on February 9, 2021, with healthcare  
60 personnel as a priority group for vaccination. During the study period (February 9 to May 4, 2021),  
61 BBIBP-CorV vaccine was the only COVID-19 vaccine available in Peru for healthcare personnel [9,  
62 10]. Two doses of BBIBP-CorV vaccine are recommended, 21 days apart. To date, BBIBP-CorV  
63 vaccine effectiveness data against SARS-CoV-2 infection have not been published in the peer-reviewed  
64 literature. Evidence on BBIBP-CorV vaccine effectiveness could reduce hesitancy about the vaccine and  
65 would support vaccination efforts. We leveraged an existing multi-year influenza cohort of healthcare  
66 workers at two Lima hospitals [11] to evaluate BBIBP-CorV vaccine effectiveness at preventing both  
67 symptomatic and asymptomatic SARS-CoV-2 infections during the study period.

68

## 69 Methods

70

### 71 *Study design*

72 From the start of COVID-19 vaccination among healthcare personnel on February 9, 2021 until May 4,  
73 2021, we followed healthcare personnel aged 18 to 65 years who were participating in an ongoing  
74 cohort of healthcare workers at two tertiary referral hospitals in Lima [11]. Inclusion criteria for cohort  
75 eligibility were: age  $\geq 18$  years; work at the facility full-time ( $\geq 30$  hours per week); have routine, direct,  
76 hands-on or face-to-face contact with patients (within 1 meter) as part of a typical work shift; and have  
77 worked at the facility for  $\geq 1$  year prior to enrollment.

78

79 Between November 25, 2020, and January 9, 2021, participants provided written informed consent and  
80 completed a baseline questionnaire about their demographics and role in the hospital (self-report  
81 exposure to COVID-19 patients (yes/no), work in intensive care unit (ICU) (yes/no), emergency  
82 department (ED) (yes/no)). Participants provided serum samples at baseline and at the end of the study  
83 period. Each participant was followed for 16 weeks after enrollment. Participants responded to a weekly  
84 survey that included questions about COVID-19 exposure and receipt of BBIBP-CorV vaccine  
85 (documented by the hospitals). Participants also provided a weekly self-collected anterior nasal swab  
86 which was tested for SARS-CoV-2 by real-time reverse transcription polymerase chain reaction (rRT-  
87 PCR) at the Naval Medical Research Unit 6 (NAMRU-6) in Lima, following Centers for Disease  
88 Control and Prevention (CDC) testing protocols [12]. rRT-PCR testing was performed in pools of five  
89 samples; if positive, all five individual samples were tested separately. Serum samples were shipped to  
90 the CDC in Atlanta, Georgia, United States of America, for pan-Ig serology testing [13].

91

### 92 *Statistical analysis*

93 We described healthcare personnel demographics, occupational information, baseline serology, COVID-  
94 19 vaccine receipt and laboratory detection of SARS-CoV-2. We applied Chi-square or Wilcoxon tests,

95 as appropriate, to assess differences in demographics, occupational information, and baseline serology,  
96 stratified by SARS-CoV-2 detection and COVID-19 vaccine receipt.

97  
98 We estimated vaccine effectiveness using a multivariable logistic regression model adjusted for pre-  
99 selected characteristics [i.e., age, sex, exposure to COVID-19 patients, work in ICU, ED, body mass  
100 index (BMI), and time of follow-up in days] and presented vaccine effectiveness estimates [(1-Odds  
101 Ratio) x100%] with 95% confidence intervals (CI). For these analyses, we excluded those who were  
102 seropositive at baseline and those with a positive COVID-19 test before February 9, 2021. We defined  
103 full vaccination as the period starting 14 days after receipt of the second dose and partial vaccination as  
104 the period starting 14 days after receipt of the first dose. Participants not meeting these criteria were  
105 considered unvaccinated. The partial vaccination model only included those who received one dose of  
106 the vaccine during the study period. Partially vaccinated individuals were excluded from the full  
107 vaccination analysis. COVID-19 vaccine effectiveness was calculated under both full and partial  
108 vaccination scenarios. The outcome of interest in the model was SARS-CoV-2 detection; if SARS-CoV-  
109 2 was detected in an individual before first vaccination date or before the two-week period after first  
110 vaccination, he/she would be considered unvaccinated for the analysis. All analyses were conducted in R  
111 (R version 4.1.0).

### 112 113 *Ethics*

114 This study was reviewed and approved by the NAMRU6 IRB as the single IRB (sIRB) for this study<sup>§</sup>.

### 115 116 *Results*

#### 117 *Study sample characteristics, SARS-CoV-2 infections and COVID-19 vaccine receipt*

118 Two hundred and ninety cohort participants were followed between February 9 and May 4, 2021, of  
119 which 270 (93.1%) reported receiving at least one dose of COVID-19 vaccine; of these, 80% (216/270)  
120 reported being fully vaccinated before the end of follow-up. The follow-up period after vaccination  
121 ranged 1-11 weeks after the two-week post-vaccination period; median of 2 weeks. Median age of  
122 participants was 45 years (IQR: 38, 52). Three out of four (74%; 215/290) participants were female and  
123 90% (260/290) reported being of mixed race. Only 3% (8/290) reported a chronic medical condition,  
124 including asthma, diabetes, high blood pressure, chronic heart disease, autoimmune condition,  
125 HIV/AIDS, or other medical condition requiring clinical care for at least 6 months. Of 290 participants,  
126 49% (n=143) were classified as overweight and 22% (n=64) as obese. One third (106/290) of  
127 participants' baseline sera had a reactive result for SARS-CoV-2 pan-Ig antibodies, and SARS-CoV-2  
128 was detected by rRT-PCR among 25 (9%) participants during follow-up. Those seronegative at baseline  
129 were more likely to subsequently test positive for SARS-CoV-2 through rRT-PCR than those  
130 seropositive at baseline (p-value<0.001; Table 1).

#### 131 132 *COVID-19 vaccine effectiveness*

133 After excluding those seropositive at baseline and those with a positive COVID-19 test before February  
134 9, 2021, and adjusting for age, sex, exposure to COVID-19 patients, work in ICU, work in ED, BMI,  
135 and time of follow-up in days, COVID-19 vaccine effectiveness against SARS-CoV-2 infection (either  
136 symptomatic or asymptomatic) was estimated as 97% (95% CI: 88%, 99%) for those who received at  
137 least one dose of the vaccine; 100% (95% CI: 88%, 100%) for those partially vaccinated, and 95% (95%  
138 CI: 70%, 99%) for those fully vaccinated (Table 2).

---

<sup>§</sup> See 45 C.F.R. part 46.114; 21 C.F.R. part 56.114

139

140 Discussion

141

142 Among those vaccinated in this cohort, we estimate BBIBP-CorV vaccine was  $\geq 90\%$  effective in  
143 preventing infection with SARS-CoV-2 in the weeks immediately following vaccination. To our  
144 knowledge, this is the first peer-reviewed data of BBIBP-CorV vaccine effectiveness against SARS-  
145 CoV-2 infection. Furthermore, our findings indicate that during the study period (February to May  
146 2021), one in ten study participants in two tertiary hospitals in Lima were infected with laboratory-  
147 confirmed SARS-CoV-2.

148 Healthcare personnel are at increased risk of becoming infected with SARS-CoV-2 [14]. Our findings  
149 show continued detection of SARS-CoV-2 infection during the study period. In Peru, it is estimated that  
150  $>600$  physicians and nurses have died of COVID-19 through June 2021 [1]. Protecting the healthcare  
151 workforce is a global priority to ensure delivery of healthcare to the population. The World Health  
152 Organization (WHO) Strategic Advisory Group of Experts on Immunization (SAGE) roadmap for  
153 prioritizing use of COVID-19 vaccines in the context of limited supplies includes healthcare personnel  
154 as one of the highest priority groups for vaccination [15]. The government of Peru initiated their  
155 COVID-19 vaccination on February 9, 2021, with healthcare personnel being the initial targeted group  
156 to receive the vaccine [16].

157 Our study indicates the BBIBP-CorV vaccine is effective against SARS-CoV-2 infection in the  
158 immediate period after vaccination. Our findings are compatible with those reported by WHO where  
159 BBIBP-CorV vaccine efficacy was estimated as 78.9% (95% CI: 65.8%-87%) against COVID-19  
160 disease in an unpublished clinical trial, with a follow-up time of two months [17]. Furthermore, our  
161 findings are consistent with interim estimates published by WHO, which estimated that vaccine  
162 effectiveness against rt-PCR confirmed cases among adults 18 years of age and older in Bahrain was  
163 90% (95% CI: 88%, 91%) [18].

164 In our study, we suspect that B.1.1.1 was the dominant circulating variant in early 2021, as it was  
165 detected in 43% of the samples that were sequenced ( $n=23$ ). However, SARS-CoV-2 variant P.1 was  
166 identified for the first time in Peru in January 2021 [19] and P.1 was identified in one out of 19 samples  
167 that were collected in January and February 2021 (data not shown); this strain emerged in Brazil in mid-  
168 November and rapidly spread in the state of Amazonas in early 2021, causing several hospitalizations  
169 and deaths [20, 21]. WHO included P.1 as one of four variants of concern in January 2021 because of its  
170 increased transmissibility and virulence [22]. It is important to maintain data collection over time to  
171 assess vaccine effectiveness under real-life circumstances while new variants circulate.

172 Due to high COVID-19 morbidity and mortality, BBIBP-CorV vaccine was rolled out in Peru and  
173 numerous other countries despite not having robust effectiveness data [23]. Though long-term  
174 effectiveness data are still needed, the results from our study support BBIBP-CorV's continued use, at  
175 least in the absence of available vaccines with proven long-term effectiveness. Data from this study can  
176 be used to support vaccination in the region; presenting vaccine effectiveness data can improve vaccine  
177 uptake [24]. Unlike some other COVID-19 vaccines, BBIBP-CorV has the advantage that it does not  
178 require complicated cold chain logistics, such as ultralow freezer conditions; instead, it can be used  
179 within the existing cold chain infrastructure of national immunization programs [25].

180 This study had several noteworthy strengths. This prospective cohort study was rapidly implemented by  
181 leveraging an ongoing prospective cohort established to evaluate influenza vaccine effectiveness among  
182 healthcare personnel with weekly swabbing and testing for SARS-CoV-2, regardless of symptoms. This  
183 frequency and breadth of sampling among our cohort allowed for greater detection of infection than in

184 passive surveillance systems. Participation rate in this COVID-19 study was high (85%) and remained  
185 high throughout the 16-week follow-up period (>96% of participants submitted specimens in at least 13  
186 of the 16 weeks of follow-up). SARS-CoV-2 infection was confirmed through rRT-PCR in NAMRU-6's  
187 high proficiency laboratory, following CDC's SARS-CoV-2 diagnostic protocol, and did not rely on  
188 point of care testing with less sensitive assays.

189 This study had at least four limitations. The high vaccine effectiveness we observed may be related to  
190 the short follow-up period after vaccination (range: 1-11 weeks after the two-week post-vaccination  
191 period; median of 2 weeks); a longer follow-up period is necessary to fully evaluate the long-term  
192 effectiveness of the vaccine among this study population. In addition, the study was not sufficiently  
193 powered to stratify VE estimates by variant or symptomatic vs asymptomatic infection. Moreover,  
194 because of the limited availability of laboratory staff and high volume of weekly respiratory specimens,  
195 we implemented a pooling strategy for SARS-CoV-2 testing which may have decreased sensitivity to  
196 detect those with low viral shedding. Last, our study could not distinguish nasal carriage of the virus  
197 from lower respiratory tract infection.

198 In summary, one in ten healthcare personnel in our study in Peru tested positive for SARS-CoV-2 during  
199 February to May 2021. Vaccination of healthcare personnel with BBIBP-CorV vaccine was effective at  
200 reducing SARS-CoV-2 infections in the weeks immediately following vaccination. The data presented  
201 in this study supports the Peruvian Government's ongoing COVID-19 vaccination efforts for reducing  
202 SARS-CoV-2 infections, especially among this critical workforce of healthcare professionals.

203

204

205

206

207

208 Disclaimer

209 The findings and conclusions in this report are those of the authors and do not necessarily represent the  
210 views of the US Centers for Disease Control and Prevention, the Department of the Navy, Department  
211 of Defense, nor the US Government.

212

213 Acknowledgments

214 We thank the participants who enrolled in the study; Nia Mims for the establishment of the CDC-DOD  
215 Interagency Agreement; the International Reagent Resource Team at CDC, Influenza Division; the CDC  
216 COVID-19 response teams: International Task Force, Laboratory Task Force. We also thank Miriam  
217 Gonzalez and Sayda La Rosa for supervision and work with field workers collecting data and samples;  
218 Fiorela Alvarez and Rocio Mananita for their clinical support during surveillance activities; NAMRU-6  
219 Laboratory Team, LCDR Paul Graf, LCDR Stephen Lizewski, LT Eugenio Abente, Roger Castillo,  
220 Anilu Tecco, for their extraordinary support and hard work processing samples; Vicky Arnao for  
221 administrative support.

222

223 Financial Disclosure

224 The study was funded through CDC Interagency Agreement 19FED1916949IPD.

225

226 The study protocol was approved by the U.S. Naval Medical Research Unit 6 (NAMRU-6) Institutional  
227 Review Board in compliance with all applicable federal regulations governing the protection of human  
228 subjects.

229

230 Copyright Statement

231 I am a federal employee of the United States government. This work was prepared as part of my official  
232 duties. Title 17 U.S.C. 105 provides that 'copyright protection under this title is not available for any  
233 work of the United States Government.' Title 17 U.S.C. 101 defines a U.S. Government work as work  
234 prepared by a military service member or employee of the U.S. Government as part of that person's  
235 official duties.

236

237 Competing interests

238 All authors report no potential conflicts.

239

240

241

242 References

- 243
- 244
- 245 1. Colegio Medico del Peru. *Medicos fallecidos for covid-19 en Iberoamerica*. 2021 [cited 2021
- 246 June 27th]; Available from: [https://www.cmp.org.pe/medicos-fallecidos-por-covid-19-en-](https://www.cmp.org.pe/medicos-fallecidos-por-covid-19-en-iberoamerica/)
- 247 [iberoamerica/](https://www.cmp.org.pe/medicos-fallecidos-por-covid-19-en-iberoamerica/).
- 248 2. Fraser, B., *COVID-19 strains remote regions of Peru*. Lancet, 2020. **395**(10238): p. 1684.
- 249 3. Alvarez-Risco, A., C.R. Mejia, J. Delgado-Zegarra, S. Del-Aguila-Arcentales, et al., *The Peru*
- 250 *Approach against the COVID-19 Infodemic: Insights and Strategies*. Am J Trop Med Hyg, 2020.
- 251 **103**(2): p. 583-586.
- 252 4. Munayco, C., G. Chowell, A. Tariq, E.A. Undurraga, et al., *Risk of death by age and gender*
- 253 *from CoVID-19 in Peru, March-May, 2020*. Aging (Albany NY), 2020. **12**(14): p. 13869-13881.
- 254 5. Calderon-Anyosa, R.J.C. and J.S. Kaufman, *Impact of COVID-19 lockdown policy on homicide,*
- 255 *suicide, and motor vehicle deaths in Peru*. Prev Med, 2021. **143**: p. 106331.
- 256 6. Pan American Health Organization. *COVID-19 Region of the Americas Update*. 2021 [cited
- 257 2021 June 27th]; Available from: [https://iris.paho.org/bitstream/handle/10665.2/54325/COVID-](https://iris.paho.org/bitstream/handle/10665.2/54325/COVID-19DailyUpdate17June2021_eng.pdf?sequence=1&isAllowed=y)
- 258 [19DailyUpdate17June2021\\_eng.pdf?sequence=1&isAllowed=y](https://iris.paho.org/bitstream/handle/10665.2/54325/COVID-19DailyUpdate17June2021_eng.pdf?sequence=1&isAllowed=y).
- 259 7. World Health Organization. *WHO Coronavirus (COVID-19) Dashboard*. [cited 2021 June
- 260 26th]; Available from: <https://covid19.who.int/region/amro/country/pe/>.
- 261 8. REUTERS. *Médicos en Perú se declaran en huelga de hambre por más inversión en salud en*
- 262 *plena segunda ola*. 2021 [cited 2021 June 27th]; Available from:
- 263 <https://www.reuters.com/article/salud-coronavirus-peru-huelga-idLTAKBN29O2R7>.
- 264 9. Government of Peru. *Resolución Ministerial N° 848-2020-MINSA. Plan Nacional de*
- 265 *Vacunación contra la COVID-19*. 2020 [cited 2021 June 26th]; Available from:
- 266 <https://www.gob.pe/institucion/minsa/normas-legales/1293043-848-2020-minsa>.
- 267 10. Government of Peru. *Resolución Ministerial N° 023-2021-MINSA. CENARES se encargue de*
- 268 *ejecutar el Acuerdo de Compraventa con la empresa SINOPHARM*. 2021 [cited 2021 June
- 269 26th]; Available from: [https://www.gob.pe/institucion/minsa/normas-legales/1475842-023-2021-](https://www.gob.pe/institucion/minsa/normas-legales/1475842-023-2021-minsa)
- 270 [minsa](https://www.gob.pe/institucion/minsa/normas-legales/1475842-023-2021-minsa).
- 271 11. Wesley, M.G., G. Soto, C.S. Arriola, M. Gonzales, et al., *Prospective cohort study of influenza*
- 272 *vaccine effectiveness among healthcare personnel in Lima, Peru: Estudio Vacuna de Influenza*
- 273 *Peru, 2016-2018*. Influenza Other Respir Viruses, 2020. **14**(4): p. 391-402.
- 274 12. CDC. *CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel*. Last
- 275 updated 12/01/2020 [cited 2021 June 26th]; Available from:
- 276 <https://www.fda.gov/media/134922/download>.
- 277 13. Freeman, B., S. Lester, L. Mills, M.A.U. Rasheed, et al., *Validation of a SARS-CoV-2 spike*
- 278 *protein ELISA for use in contact investigations and serosurveillance*. bioRxiv, 2020.

- 279 14. Nguyen, L.H., D.A. Drew, M.S. Graham, A.D. Joshi, et al., *Risk of COVID-19 among front-line*  
280 *health-care workers and the general community: a prospective cohort study*. *Lancet Public*  
281 *Health*, 2020. **5**(9): p. e475-e483.
- 282 15. World Health Organization. *WHO SAGE Roadmap For Prioritizing Uses Of COVID-19*  
283 *Vaccines In The Context Of Limited Supply*. 2020 [cited 2021 July 6th]; Available from:  
284 [https://www.who.int/publications/i/item/who-sage-roadmap-for-prioritizing-uses-of-covid-19-](https://www.who.int/publications/i/item/who-sage-roadmap-for-prioritizing-uses-of-covid-19-vaccines-in-the-context-of-limited-supply)  
285 [vaccines-in-the-context-of-limited-supply](https://www.who.int/publications/i/item/who-sage-roadmap-for-prioritizing-uses-of-covid-19-vaccines-in-the-context-of-limited-supply).
- 286 16. REUTERS. *'The best shield': Peru launches inoculation drive with Sinopharm vaccine*. 2021  
287 [cited 2021 June 27th]; Available from: [https://www.reuters.com/business/healthcare-](https://www.reuters.com/business/healthcare-pharmaceuticals/the-best-shield-peru-launches-inoculation-drive-with-sinopharm-vaccine-2021-02-10/)  
288 [pharmaceuticals/the-best-shield-peru-launches-inoculation-drive-with-sinopharm-vaccine-2021-](https://www.reuters.com/business/healthcare-pharmaceuticals/the-best-shield-peru-launches-inoculation-drive-with-sinopharm-vaccine-2021-02-10/)  
289 [02-10/](https://www.reuters.com/business/healthcare-pharmaceuticals/the-best-shield-peru-launches-inoculation-drive-with-sinopharm-vaccine-2021-02-10/).
- 290 17. World Health Organization. *Annexes to the interim recommendations for use of the inactivated*  
291 *COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm* 2021  
292 [cited 2021 July 6th]; Available from: <https://apps.who.int/iris/handle/10665/347768>.
- 293 18. World Health Organization. *Evidence Assessment: Sinopharm/BBIBP COVID-19 vaccine*. 2021  
294 [cited 2021 June 27th]; Available from: [https://cdn.who.int/media/docs/default-](https://cdn.who.int/media/docs/default-source/immunization/sage/2021/april/2_sage29apr2021_critical-evidence_sinopharm.pdf)  
295 [source/immunization/sage/2021/april/2\\_sage29apr2021\\_critical-evidence\\_sinopharm.pdf](https://cdn.who.int/media/docs/default-source/immunization/sage/2021/april/2_sage29apr2021_critical-evidence_sinopharm.pdf).
- 296 19. Ministerio de Salud del Peru. *INS detectó la presencia de la variante brasileña del coronavirus*  
297 *en Loreto, Huánuco y Lima*. 2021 [cited 2021 June 27th]; Available from:  
298 [https://web.ins.gob.pe/es/prensa/noticia/ins-detecto-la-presencia-de-la-variante-brasilena-del-](https://web.ins.gob.pe/es/prensa/noticia/ins-detecto-la-presencia-de-la-variante-brasilena-del-coronavirus-en-loreto-huanuco)  
299 [coronavirus-en-loreto-huanuco](https://web.ins.gob.pe/es/prensa/noticia/ins-detecto-la-presencia-de-la-variante-brasilena-del-coronavirus-en-loreto-huanuco).
- 300 20. Faria, N.R., T.A. Mellan, C. Whittaker, I.M. Claro, et al., *Genomics and epidemiology of a novel*  
301 *SARS-CoV-2 lineage in Manaus, Brazil*. medRxiv, 2021.
- 302 21. Naveca, F.G., V. Nascimento, V.C. de Souza, A.L. Corado, et al., *COVID-19 in Amazonas,*  
303 *Brazil, was driven by the persistence of endemic lineages and P.1 emergence*. *Nat Med*, 2021.
- 304 22. World Health Organization. *Tracking SARS-CoV-2 variants*. 2021 [cited 2021 July 6th];  
305 Available from: <https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/>.
- 306 23. Pan American Health Organization. *COVID-19 Vaccination in the Americas*. 2021 [cited 2021  
307 July 19th]; Available from: [https://ais.paho.org/imm/IM\\_DosisAdmin-Vacunacion.asp](https://ais.paho.org/imm/IM_DosisAdmin-Vacunacion.asp).
- 308 24. Kaplan, R.M. and A. Milstein, *Influence of a COVID-19 vaccine's effectiveness and safety*  
309 *profile on vaccination acceptance*. *Proc Natl Acad Sci U S A*, 2021. **118**(10).
- 310 25. Acharya, K.P., T.R. Ghimire, and S.H. Subramanya, *Access to and equitable distribution of*  
311 *COVID-19 vaccine in low-income countries*. *NPJ Vaccines*, 2021. **6**(1): p. 54.

312  
313  
314  
315



## Tables & Figures

Table 1: Demographic, occupational information, baseline serology, COVID-19 vaccine receipt and laboratory detection of SARS-CoV-2 among healthcare personnel cohort participants, Lima-Peru, February 9 to May 4, 2021, N=290

	Total N=290 (100%)	SARS-CoV-2 positive * n=25 (9%)	SARS-CoV-2 negative n=265 (91%)	p-value□	Unvaccinated n=20 (7%)	Partially vaccinated** n=54 (19%)	p-value□	Fully vaccinated** n=216 (74%)	p-value□
Age (years)									
Median (IQR)	45 (38,52)	48 (41, 54)	45 (38,51)		39 (37,49)	47 (39, 52)		45 (39,52)	
18-39	85 (29)	6 (24)	79 (30)	0.82	10 (50)	14 (26)	0.14	61 (28)	0.12
40-49	110 (38)	10 (40)	100 (38)		5 (25)	22 (41)		83 (38)	
50-65	95 (33)	9 (36)	86 (32)		5 (25)	18 (33)		72 (33)	
Gender									
Male	75 (26)	6 (24)	69 (26)	1.0	1 (5)	25 (46)	<0.01	49 (23)	0.12
Female	215 (74)	10 (76)	196 (74)		19 (95)	29 (54)		167 (77)	
Race/Ethnicity									
Mixed race	260 (90)	21 (84)	239 (90)	0.45	19 (95)	45 (83)	0.48	196 (91)	0.89
Indigenous	19 (7)	2 (8)	17 (6)		1 (5)	3 (6)		15 (7)	
Black	8 (3)	1 (4)	7 (3)		0 (0)	5 (9)		3 (1)	
White	3 (1)	1 (4)	2 (1)		0 (0)	1 (2)		2 (1)	
Education									
High school education only	37 (13)	2 (8)	35 (13)	0.75	0 (0)	13 (24)	0.02	24 (11)	0.10
Associate degree from college or equivalent/Bachelor's degree	233 (80)	21 (84)	212 (80)		20 (100)	38 (70)		175 (81)	
Postgraduate education	20 (7)	2 (8)	18 (7)		0 (0)	3 (6)		17 (8)	
Comorbidities									
Any medical condition**	8 (3)	2 (8)	6 (2)	0.52	1 (5)	2 (4)	0.74	5 (2)	0.64
BMI									

Normal (18.5 to <25)	83 (29)	9 (36)	74 (28)		9 (45)	17 (31)		57 (26)	
Overweight (25 to <30)	143 (49)	12 (48)	131 (49)	0.61	7 (35)	27 (50)	0.47	109 (50)	0.20
Obese (≥30)	64 (22)	4 (16)	60 (23)		4 (20)	10 (19)		50 (23)	
Smoking (daily/some)	11 (4)	1 (4)	10 (4)	1.0	1 (5)	3 (6)	1.0	7 (3)	1.0
Job type									
Physician	11 (4)	1 (4)	10 (4)		0 (0)	0 (0)		11 (5)	
Nurse	63 (22)	2 (8)	61 (23)		1 (5)	10 (19)		52 (24)	
Midwife/Dentist	12 (4)	1 (4)	11 (4)		0 (0)	0 (0)		12 (5)	
Technician/assistant	135 (47)	14 (56)	121 (46)		15 (75)	17 (31)		103 (48)	
Pharmacist/social worker/nutritionist	2 (1)	0 (0)	2 (1)	0.62	1 (5)	0 (0)	<0.01	1 (0)	0.08
Physical therapist	4 (1)	0 (0)	4 (2)		0 (0)	2 (4)		2 (1)	
Admin/security/maintenance/Transporter	49 (17)	7 (28)	42 (15)		1 (5)	20 (37)		28 (12)	
Other	14 (5)	0 (0)	14 (5)		2 (10)	5 (9)		7 (3)	
Exposed to COVID-19 Patients in healthcare setting	249 (86)	18 (72)	231 (87)	0.59	17 (85)	45 (83)	1.0	187 (87)	1.0
Work in ICU	27 (9)	4 (16)	23 (9)	0.40	0 (0)	8 (15)	0.16	19 (9)	0.34
Work in Emergency Department	101 (35)	11 (44)	90 (34)	0.43	9 (45)	20 (37)	0.72	72 (33)	0.42
Number of work hours at site per week (median, IQR)	36 (36,36)	36 (36,40)	36 (36,36)	0.93	36 (36,39)	36 (36,48)	0.23	36 (36,36)	0.40
Number of patient-provider face-to-face hours per week (median, IQR)	30 (24,36)	30 (20,30)	30 (25,36)	0.04	33 (30,37)	30 (25,36)	0.31	30 (24,36)	0.11
Reactive SARS-CoV-2 serology at baseline	106 (37)	0 (0)	106 (40)	<0.001	5 (25)	15 (28)	1.0	86 (40)	0.28

Notes:

\* At least once by weekly testing during follow-up period

\*\*Vaccination of healthcare workers started in Lima on February 9, 2021 and was assessed by interview on a weekly basis. Partially vaccinated refers to those who received 1 dose of whole virus COVID-19 vaccine during the study period; fully vaccinated refers to those who received 2 doses of whole virus COVID-19 vaccine during the study period

\*\*\*Asthma, diabetes, high blood pressure, chronic heart disease, autoimmune condition, HIV/AIDS, another medical condition requiring clinical care for at least 6 months

□ Chi-square test for categorical and Wilcoxon signed rank test for continuous variables. Partially and fully vaccinated groups were compared to unvaccinated individuals, separately

Table 2. COVID-19 vaccine effectiveness (VE) by dose received among healthcare personnel cohort participants, Lima-Peru, February 9 to May 4, 2021

	COVID-19 Cases		Controls		Unadjusted VE % (95% CI)	Adjusted VE* % (95% CI)
	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated		
<i>Received at least one dose of vaccine</i>	10	9	138	6	95% (84%, 99%)	97% (88%, 99%)
<i>Fully vaccinated</i>	5	9	36	6	91% (63%, 98%)	95% (70%, 99%)
<i>Partially vaccinated</i>	5	9	25	6	87% (45%, 97%)	100% (88%, 100%)

\*Adjusted for age, sex, exposure to COVID-19 patients, work in ICU, work in ER, BMI, and time of follow-up.

Note1: Those with reactive SARS-CoV-2 serology at baseline have been excluded (n=106).

Note2: Those with a positive COVID-19 test before February 9, 2021 have been excluded (n=17).

Note3: Those who had tested positive before vaccination date or before the 2-week period after vaccination were considered unvaccinated for the model.

Note 4: We defined full vaccination as the period starting 14 days after receipt of the second dose and partial vaccination as the period starting 14 days after receipt of the first dose. Participants not meeting these criteria were considered unvaccinated. The partial vaccination model only included those who received one dose of the vaccine during the study period.

